Treatment timing
Assessment, sampling, manufacture, admission and follow-up are separate stages. Obtain the centre’s plan before arranging travel; a technology name does not establish a fixed duration.
All oncology programmes
Immune-cell therapies
TCR-T engineered T-cell therapy
Engineered T-cell receptors recognise antigen fragments presented by HLA. Antigen testing and HLA typing are central to assessment.
TCR-T
- Technology basis
- Engineered T-cell receptors
- Samples and tests
- Antigen tests and HLA typing
- Key feature
- Product and programme verification
Overview
TCR-T engineers the T-cell receptor. Unlike CAR-T’s direct recognition of cell-surface targets, these receptors recognise antigen fragments presented through HLA molecules. Both tumour-antigen expression and the patient’s HLA type may affect eligibility.
How it works
- 01
Confirm antigen and HLA
Test tumour antigens and match the HLA types required by the approach.
- 02
Engineer receptors
Collected T cells undergo specialist manufacturing to express the intended receptor.
- 03
Recognise presented fragments
Infused cells recognise the corresponding antigen fragments; the team assesses response.
This illustrates the mechanism. Antigen-specific immune responses do not establish clinical benefit, which requires separate evidence.
Technology approach
Common autologous pathways include testing, collection, engineered manufacture, conditioning and intravenous infusion. Interim treatment, admission and long-term monitoring follow the actual product or protocol.
Samples and manufacturing process
This outlines the main technical stages. Sampling, manufacturing and quality-testing time vary with the protocol and samples.
- 01
Pathology and typing
Confirm antigens, HLA and eligibility.
- 02
Collection and manufacture
Arrange collection, manufacture and care during the interval.
- 03
Conditioning and infusion
Reassess and deliver treatment with specialist monitoring.
- 04
Safety and disease follow-up
Record adverse effects and reassess disease as scheduled.
Samples and assessment considerations
- Pathology and prior treatments against product or study criteria.
- Required antigen expression and HLA type.
- Collection, manufacturing and conditioning feasibility, organ function and infections.
Monitoring and follow-up
Monitoring after treatment
Continue product- or study-required safety follow-up and review imaging, symptoms and laboratory results. An antigen test alone does not determine response.
Risks to discuss
Risks include cytokine release syndrome, infection, low blood counts and other serious reactions. The programme must explain unintended-antigen recognition risks and monitoring.
During treatment, severe symptoms such as high fever, breathing difficulty or altered awareness require immediate contact with the medical team or local emergency services. Do not wait for an enquiry email response.
Records for assessment
Start with a diagnosis summary and a list of existing reports. Send full records through the agreed private channel. Clinicians decide whether missing tests are necessary; do not arrange every test independently.
- Pathology reports and available specimen details
- Previous regimens, dates and responses
- Recent imaging reports and available image files
- Existing molecular, target or HLA tests
- Other conditions, current medicines and allergies
- Preferred timing, caregiver and return-travel plans
Timing, travel and costs
Cost components
Review tests, manufacture or medicines, admission, supportive care and follow-up separately. Study cost coverage depends on its documents; confirm insurance in writing. Formal centre and service quotations govern charges.
Follow-up at home
Before leaving, confirm reviews, emergency contacts and coordination with local clinicians. Travel plans cannot replace decisions about admission or nearby observation.
Common questions
What if the antigen is positive but HLA does not match?
That may exclude the proposed approach. Discuss alternatives with the physician; the HLA criterion cannot be bypassed.
Are TCR-T and CAR-T the same?
No. Receptors and antigen recognition differ, as do testing, product evidence and clinical criteria.
Related programmes
CAR-T
CAR-T cell therapy
Explore the programmeTILTIL: tumour-infiltrating lymphocytes
Explore the programmePeptidePersonalised neoantigen peptide vaccine
Explore the programmeProgramme enquiries and records
HuaCure helps organise existing records, clarify programme requirements and coordinate specialist enquiries. Explore the technology, then discuss your circumstances with the medical team.
This website provides information, not medical advice. Healthcare providers assess diagnosis, treatment suitability, risks and research eligibility. HuaCure coordinates care and does not guarantee outcomes or study enrolment.
Compiled from programme technical materials and public medical sources to explain mechanisms and processes. It is not an individual medical recommendation or a promise of benefit.
Sources
Public information checked: 7 October 2026